ALTH Receives Priority Review from FDA for Cancer Drug |
 |
 |
| Tuesday, 26 May 2009 09:25 |
 Allos Therapeutics (NASDAQ:ALTH) Receives Priority Review Designation for Cancer Drug: Filed NDA on 3/25/09 with FDA for pralatrexate in the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). ALTH received a priority (six-month) review designation on 5/26/09 with a PDUFA decision date of 9/24/09. PTCL comprises a biologically diverse group of hematologic malignancies that typically has a worse prognosis than other types of lymphoma and is less responsive to traditional chemotherapy regimens. There are currently no agents approved by the FDA for the treatment of patients with PTCL.
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
